Orforglipron: the first GLP-1 pill that is not a peptide

A small molecule for a peptide receptor

The GLP-1 receptor responds to a peptide hormone, and the most widely used drugs in the class, such as semaglutide, are peptides⁸. Orforglipron is different: it is a small, non-peptide molecule that activates the same receptor and is taken once daily by mouth¹². In healthy volunteers, its absolute oral bioavailability was 79.1%, and it was eliminated mainly in feces (87%)⁷. It was designed to be taken without food or water restrictions⁴.

The contrast is oral semaglutide, which is still a peptide. To be absorbed it needs the enhancer SNAC: absorption takes place in the stomach, in the area close to the tablet surface, and does not occur without that coformulation⁸. That is why the semaglutide pill must be taken on an empty stomach¹⁴.

What phase 3 showed

In ACHIEVE-1 (559 adults with early type 2 diabetes on diet and exercise only), HbA1c fell 1.24, 1.47 and 1.48 points with 3, 12 and 36 mg vs 0.41 with placebo at 40 weeks; body weight changed −4.5%, −5.8% and −7.6% vs −1.7%. There was no severe hypoglycemia, and discontinuation due to adverse events was 4.4–7.8% vs 1.4%¹.

In ATTAIN-1 (3127 adults with obesity without diabetes, 72 weeks), body weight changed −7.5%, −8.4% and −11.2% with 6, 12 and 36 mg vs −2.1% with placebo (treatment-regimen estimand). With 36 mg, 54.6% lost at least 10% and 18.4% at least 20%². In ATTAIN-2 (1613 adults with obesity and type 2 diabetes), the reduction was −9.6% with 36 mg vs −2.5%³. The estimand difference that explains why these figures look smaller than some press releases was covered in After semaglutide.

On cardiovascular safety, ACHIEVE-4 (2749 high-risk adults with type 2 diabetes) was non-inferior to insulin glargine for major adverse cardiovascular events: 4.2% vs 5.0% (HR 0.84; 95% CI 0.59–1.20). The authors note that, until this trial, the cardiovascular safety of a non-peptide agonist "has not been studied"⁵. Clinically significant hypoglycemia was less frequent (6.8% vs 19.2%) and gastrointestinal events more frequent (62.1% vs 14.2%)⁵.

Against the other pill: oral semaglutide

The only published head-to-head trial against a peptide that we found is ACHIEVE-3, in 1698 adults with type 2 diabetes on metformin, over 52 weeks. Orforglipron 12 and 36 mg lowered HbA1c by 1.71 and 1.91 points vs 1.23 and 1.47 with oral semaglutide 7 and 14 mg: non-inferior and superior in all comparisons. In exchange, there were more gastrointestinal events (58–59% vs 37–45%), more discontinuations due to adverse events (9–10% vs 4–5%) and a larger rise in pulse rate (3.7–4.7 vs 1.0–1.5 beats per minute). The trial was open-label and funded by Lilly⁴.

In obesity, oral semaglutide 25 mg (OASIS 4, 307 adults) was associated with −13.6% body weight at 64 weeks vs −2.2% with placebo, with gastrointestinal events in 74.0% vs 42.2%⁹. There is no direct trial against orforglipron. A population-adjusted indirect comparison by Novo Nordisk employees estimated a −3.2 percentage-point difference favoring oral semaglutide 25 mg and fewer discontinuations due to adverse events (OR 4.1 against orforglipron)¹⁰. It is an indirect estimate from the competing manufacturer and should be read as such.

And against the injectable peptides?

We found no published trials directly comparing orforglipron with injectable semaglutide or tirzepatide in obesity. What exists are separate placebo-controlled trials: −14.9% at 68 weeks with weekly semaglutide 2.4 mg in STEP 1¹¹ and −20.9% at 72 weeks with tirzepatide 15 mg in SURMOUNT-1¹², vs −11.2% with orforglipron 36 mg in ATTAIN-1². Populations, eras and placebo responses differ, so the figures are a guide but do not prove superiority. Investigator Deborah Horn put it this way: "It's not as high of weight loss as tirzepatide"¹⁴.

Where the pill did show a clear role is maintenance. In ATTAIN-MAINTAIN, adults who had lost weight on injectable tirzepatide or semaglutide switched to orforglipron or placebo. At 52 weeks, they kept an estimated 74.7% and 79.3% of the loss with orforglipron vs 49.2% and 37.6% with placebo⁶. The authors themselves list as a limitation that there was no arm continuing the injectable⁶.

Approval, price and scale

The FDA approved orforglipron, brand name Foundayo, on 1 April 2026, to reduce excess body weight and maintain weight reduction long term in adults with obesity, or with overweight and at least one comorbidity, alongside diet and physical activity¹³. That approval does not cover type 2 diabetes; as of this article we found no FDA approval for that indication¹³. Trial doses (up to 36 mg capsule) differ from the commercial tablet: 36 mg in capsule is equivalent to 17.2 mg in tablet⁵.

According to Scientific American, the US self-pay price ranges from $149 to $349 per month depending on dose, and the semaglutide pill for obesity had been approved in December 2025¹⁴. The same outlet notes that small molecules are generally easier and cheaper to make than peptides, and avoid cold chain and injection pens¹⁴.

What it means for the peptide market

The data support a two-sided reading. On one hand, a pill without food restrictions, easy to manufacture at scale, can reach patients who refuse injections or currently lack access, and can help maintain weight after an injectable⁶¹⁴. On the other, in obesity the largest published weight losses still belong to injectable peptides, and in the only direct comparison with an oral peptide orforglipron won on glucose but was less well tolerated⁴¹¹¹². The industry behind both products was described in the industry in numbers, and the next wave of more potent peptides in retatrutide.